Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages 18-75~2. HIV+~3. Clinically significant fatigue (score of 4.5+ on Fatigue Severity Scale, plus impairment on 1+ categories of Role Function Scale)~4. Fatigue duration for 3+ months~5. English-speaking~6. Able to give informed consent~7. Fecund women uses barrier method of contraception~Exclusion Criteria:~1. Primary care doctor does not approve of study participation~2. Unstable medical condition (e.g. liver failure; cirrhosis, new onset opportunistic infection in past month)~3. Untreated hypogonadism, except for men for whom testosterone replacement is medically contraindicated (serum testosterone below the reference range)~4. Untreated hypothyroidism (Thyroid Stimulating Hormone over 5 IUI/mL)~5. Untreated and uncontrolled hypertension~6. Clinically significant anemia (hematocrit \<30%)~7. Started testosterone or nandrolone in past 6 weeks~8. Started or changed an antiretroviral regimen in past 4 weeks if fatigue predated the change; otherwise, started or changed regimen in past 2 months~9. Untreated or under-treated major depressive disorder~10. Started antidepressant medication within past 6 weeks~11. Substance abuse/dependence (past 4 months)~12. Regular and frequent cannabis use (\> twice/week regularly)~13. Currently clinically significant suicidal ideation or Hamilton Depression Scale (HAM-D) score \>24~14. History or current psychosis or bipolar disorder~15. Pregnant or breastfeeding~16. Significant untreated insomnia (score \>3 on HAM-D insomnia items)~17. Currently taking psychostimulant medication or past nonresponse to modafinil~18. Has no alternative viable antiretroviral regimen after the current one~19. Left ventricular hypertrophy; mitral valve prolapse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Armodafinil (Type: EXPERIMENTAL): Participants will take armodafinil for 4 weeks. The dose will be titrated up from 50mg to 250mg per day as clinically indicated, using 50mg tablets. If responsive, participants will be offered 12 additional weeks of armodafinil.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo pills for 4 weeks. Placebo tablets that match the 50mg active medication tablets will given following the same dosing strategy as Arm 1. The dose will be titrated from 1 placebo tablet daily to 5 tablets daily as clinically indicated. Non-responders to placebo will then be offered 16 weeks of active medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).